Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men
about
Insights on common vaccinations in HIV-infection: efficacy and safetyOral human papillomavirus infection and head and neck cancers in HIV-infected individualsThe rising challenge of non-AIDS-defining cancers in HIV-infected patientsScreening guidelines for non-AIDS defining cancers in HIV-infected individualsSafety of human papillomavirus vaccines: a reviewAnal dysplasia in HIV-infected women: a commentary on the field.Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United StatesSafety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)Vaccination in HIV-infected adults.Update on opportunistic infections in the era of effective antiretroviral therapyGuidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theCervical human papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia: prevalence, genotypes, risk factors and association with HIV infection.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North AmericaPrevalence and risk factors for neutralizing antibodies to human papillomavirus types 16 and 18 in HIV-positive men who have sex with menImmunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.Human papilloma virus vaccines: Current scenarioAnal Human Papillomavirus Genotyping among HIV-Positive Men Who Have Sex with Men in Xi'an, ChinaPrevalence of Anal Human Papillomavirus Infection and Risk Factors among HIV-positive Patients in Tokyo, Japan.Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients.A review of clinical trials of human papillomavirus prophylactic vaccines.HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected childrenCancer prevention in HIV-infected populations.Impact of the HIV epidemic on the incidence rates of anal cancer in the United States.The Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer.High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine.The role of viral co-infection in HIV-associated non-AIDS-related cancersComparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012.Prophylactic HPV vaccination and anal cancerHuman Papillomavirus (HPV) Infections and the Importance of HPV Vaccination.Role and uptake of human papillomavirus vaccine in adolescent health in the United StatesAnal cancer and cervical cancer screening: key differences.Human papillomavirus vaccination in males: the state of the science.Vaccination to protect against infection of the female reproductive tract.Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact.Clinical trials of human papillomavirus vaccines and beyond.
P2860
Q26770665-D25B75FE-BDC4-4278-A3B7-A6B109FD749FQ26825257-B0313D2E-4D91-4229-B2F5-F2B61C9C6BC5Q26861496-CD91F599-FAC9-460B-BE47-39CC8628F727Q27021899-B4DF1E40-059C-4004-9327-1183CAFC48B2Q28082119-76C0C21D-DF7A-4751-A1A5-0101B2407738Q30252055-517354E9-42FD-48D9-9DBA-614B46230A7DQ33166996-BF8C083E-CACD-42E5-96A0-E1A26A8DA167Q33916553-FE0CFA81-F6F4-41BF-B498-102E7DD972B3Q33980764-883B03B4-6A48-4866-8C05-3B9A97CB28D3Q34085853-86D3A531-2A99-4B1A-8729-C34D76708BE1Q34212799-ABC27120-01DA-4476-891C-37BF39DEB61AQ34354553-32AD97E3-00FD-4DE7-8A1F-527BCF4B1319Q34390072-469A0639-B145-4CEC-AF05-A7666EA08162Q34635523-47AB8B97-9BB2-4005-97F1-A8E9D9DA81C4Q34873067-C38628B3-B483-4714-B018-5D5596EDEDAFQ35008398-C93BA1EC-35E4-49E0-B9B2-7E7F0057F927Q35366075-D96B95F2-98D9-4BE8-9379-FDFE3C1BC303Q35553220-E09A5153-199F-437C-AEDB-015FB7931003Q35773936-5D100FDC-A3D3-4069-8070-E7773C3F0AE0Q36093327-84702100-F5B9-4EDC-B43E-E44EEB3DE9B3Q36259403-FE7DF78E-A998-4DDC-866F-CE46D3C1A4B5Q36368353-313BCE22-7232-496C-B646-C47AF437ED61Q36399193-339F1BE9-FC3C-40C2-A07C-D222F016ABECQ36459660-FC54EA5E-01BE-4716-90E6-62E0C93CF183Q36486823-F3038D31-7C52-48A4-AF20-F8A792BF1402Q36680086-ACCAA6DD-DEF5-4FBA-87DF-4DF14B005373Q36727400-87DFF5CD-CAAE-45CC-9DA7-F13D56ABD29DQ36788317-63CE6028-41DA-4A81-A2CB-59C3BEBB9DD3Q36911916-1385B02A-DEDA-4008-BF26-59F28ED9EE8DQ36960884-8B4EF030-8761-4094-B1C4-96D3305869C6Q36977831-3499C132-07A9-4C3A-85D2-F3C9C86C12A7Q37047999-4D4C61B2-A4E7-4C79-895E-19D97BEBFECCQ37135065-463C3904-C852-4717-A9AB-4BB9D1D02340Q37155765-99CD7ACE-6105-497A-AC7B-2C765325DD07Q37244355-FE07B5DF-0275-4EFA-AB40-123CDE79320DQ37841421-CD67F1CF-48A9-464E-BBF8-3F9491C5052EQ37848732-A10AE2F7-AD37-4F9E-92CA-9C72A03489CCQ37849708-37D6BAA6-0F21-49FF-A5D1-5BADAF6B1AE7Q37912228-AE91EB20-DD70-4BBF-BC3A-F221A54D95D2Q38111962-CF491B23-F5B4-4A22-AF25-2ED9C7548FC7
P2860
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Safety and immunogenicity of t ...... vaccine in HIV-1-infected men
@ast
Safety and immunogenicity of t ...... vaccine in HIV-1-infected men
@en
type
label
Safety and immunogenicity of t ...... vaccine in HIV-1-infected men
@ast
Safety and immunogenicity of t ...... vaccine in HIV-1-infected men
@en
prefLabel
Safety and immunogenicity of t ...... vaccine in HIV-1-infected men
@ast
Safety and immunogenicity of t ...... vaccine in HIV-1-infected men
@en
P2093
P2860
P356
P1476
Safety and immunogenicity of t ...... vaccine in HIV-1-infected men
@en
P2093
Alfred Saah
David Aboulafia
David L Cohn
J Michael Berry
Jeannette Y Lee
Joel M Palefsky
Mark H Einstein
Ronald T Mitsuyasu
Shelly Y Lensing
P2860
P304
P356
10.1086/656320
P407
P577
2010-10-01T00:00:00Z